Spotlight On... Sun sales in U.S. fall further as FDA issues linger; Novo A/S CEO to step down; Alnylam plots new $200M manufacturing plant; and more...

India's Sun Pharmaceutical saw its sales in the U.S., its largest market, continue to fall as problems with a key plant in India have yet to be resolved. U.S. sales were off 11% to $486 million in the quarter ended Dec. 31, 2015, India's largest drugmaker reported today. It did, however, benefit from its U.S. subsidiary, Taro, which saw revenues increase 9% to $258 million. Sources are telling Indian media that the drugmaker is also looking to unload a couple of plants in India that it picked up in its $4 billion buyout last year of Ranbaxy Laboratories. Earnings report (PDF) | Story | More

@FiercePharma: Startup aims to match ailing pets with clinical trials that could help people, too. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Qualicaps snags Brazil's largest hard capsule maker. Will expand in Latin America from there. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Teva's Copaxone finally succumbs to copycats, putting a drag on 2015 sales. Article | Follow @CarlyHFierce

> Eivind Kolding, CEO of Novo A/S, Novo Nordisk's ($NVO) parent, is stepping down after less than two years in the position. Report

> RNAi biotech Alnylam Pharmaceuticals ($ALNY) plans to shell out $200 million on a manufacturing plant in a bet that its pipeline therapies will advance to market. More

Medical Device News

@FierceMedDev: Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: Big Pharma shells out big campaign dollars to presidential candidates. FiercePharma article | Follow @EmilyWFierce

> GV charts its own course with big bets on med tech: Bloomberg. Story

> SI-Bone's spinal fusion implant gains near-total Medicare coverage on back of strong studies. Article

Biotech News

@FierceBiotech: Novartis buys EU rights to Pfizer's Remicade biosimilar, targeting Merck. Report | Follow @FierceBiotech

@JohnCFierce: Google cool: I spend no time fundraising," Maris tells . "Alphabet can give us as much $$ as we want. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Early theme in responses to this poll: Men much more likely to get "stretch" jobs, be lauded for ambitious failures. ICYMI from FierceBiotech | Follow @DamianFierce

> Alnylam bets $200M on its commercial future with new plant. News

> U.K.'s Shield pulls off an IPO but dramatically cuts its flotation price. Article

> Apellis raises $47M after pulling the plug on an $86M IPO. Report

And Finally... A Boston University study found the rate of dementia cases in Europeans has been decreasing, possibly because of healthier lifestyles. Report

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.